Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578929 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients
A Phase 3 study of Seasonal Allergic Rhinitis, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,388
- Enrollment target
- 1
- Study location
NCT00578929 is a Phase 3 study of Seasonal Allergic Rhinitis that has completed, run by Alcon Research. The registered enrollment target is 2,388 participants, above the 519-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (360% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00578929, a Phase 3 study of Seasonal Allergic Rhinitis, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,388 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to demonstrate the superiority of test article nasal spray relative to vehicle nasal spray for the treatment of seasonal allergic rhinitis for a 2 week period in patients aged 6 to 11 years with a history of seasonal allergic rhinitis.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG Olopatadine Hydrochloride Nasal Spray 0.6%
Study Locations (1)
Illinois
- Kenilworth/IL - Kenilworth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,388 participants |
| Start Date | 2007-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00578929
The ClinicalTrials.gov registry entry for NCT00578929 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,388 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 519-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (360% higher). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Seasonal Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT00578929 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00578929 about?
NCT00578929 is a clinical study titled "Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients". A study to demonstrate the superiority of test article nasal spray relative to vehicle nasal spray for the treatment of seasonal allergic rhinitis for a 2 week period in patients aged 6 to 11 years with a history of seasonal allergic rhinitis.
What is the current status of trial NCT00578929?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,388 participants. The study started on 2007-09.
What conditions does trial NCT00578929 study?
This clinical trial studies the following conditions: Seasonal Allergic Rhinitis.
What interventions are being tested in trial NCT00578929?
The interventions under investigation include: Vehicle (DRUG), Olopatadine Hydrochloride Nasal Spray 0.6% (DRUG).
Who is sponsoring clinical trial NCT00578929?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00578929 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seasonal Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)
COMPLETED · Phase 3
-
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
COMPLETED · Phase 3
-
A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
COMPLETED · Phase 3
-
Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies
COMPLETED · Phase 3
-
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)
COMPLETED · Phase 3
-
Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.